US.JNJ · Johnson & Johnson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.2570774185900753,
        "turnoverUsdM": 2662.7193938939995,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 253.9828,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.5,
      "take_profit_price": 280.8189,
      "target_multiplier": 1.9,
      "technical_strength": 1.95,
      "take_profit_percent": 5.6
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.240542294623226,
    "stopLossPercent": 4.5141548371801505,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 77.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 257.046,
    "ma50": 242.6422,
    "close": 265.99,
    "prevClose": 263.4,
    "avgVolume20": 8125240,
    "volumeRatio": 1.23,
    "changePercent": 0.98
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.06900562378403552,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 0,
      "vol_ratio": 1.1860127598320014,
      "ret_points": 12,
      "vol_points": 2,
      "range_ratio": 1.2376013463955398,
      "volat_points": 2,
      "day_range_pct": 0.028008497613011614,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 77.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 86,
        "contribution": 4.3
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 22.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 74.33,
        "contribution": 22.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 60.4,
    "details": [
      "基本面分析總分: 4.3/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 22.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4.3,
      "資金流": 11.6,
      "市場環境": 4.6,
      "情緒分析": 4,
      "技術信號": 22.3,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 2662.7193938939995,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 710.4899991500001,
                "ma50": 717.6342017599999,
                "name": "QQQ",
                "close": 682.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6545068500001,
                "ma50": 745.00220184,
                "name": "SPY",
                "close": 739.02002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.2570774185900753,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141037166,
                "url": "https://finnhub.io/api/news?id=47fde8cf6cf537b615efc481300dac44cba78e8550ad22fd114ca61fd3aafdec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]",
                "category": "company",
                "datetime": 1785185861,
                "headline": "Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?"
              },
              {
                "id": 141032898,
                "url": "https://finnhub.io/api/news?id=6615fc66077e5d2d0c4d94d8221ea056226840814fa58f92010b88792e506262",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]",
                "category": "company",
                "datetime": 1785158883,
                "headline": "President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling"
              },
              {
                "id": 141015072,
                "url": "https://finnhub.io/api/news?id=16830e1d8b90f829bbd5e5977c2ddc14c197164f44230010d0e383c3a2102e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson (NYSE:JNJ)’s stock is up by 15%. As the shares struggled in […]",
                "category": "company",
                "datetime": 1784966368,
                "headline": "Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next"
              },
              {
                "id": 141012125,
                "url": "https://finnhub.io/api/news?id=df9ddbba648df52ff017922094bd25e71324c6ce3d875d9a4358040044d82db0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...",
                "category": "company",
                "datetime": 1784931178,
                "headline": "Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma"
              },
              {
                "id": 141001671,
                "url": "https://finnhub.io/api/news?id=2b3d8469f528d79fb00654c130f687ab423e66a83b114c1d4335fd3db9a5f390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.",
                "category": "company",
                "datetime": 1784833972,
                "headline": "J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock."
              },
              {
                "id": 140994646,
                "url": "https://finnhub.io/api/news?id=f128455069eee81b95530f62b343bf3bb525c652a351fbc7f991a20272c72a2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.",
                "category": "company",
                "datetime": 1784813100,
                "headline": "ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook"
              },
              {
                "id": 140992107,
                "url": "https://finnhub.io/api/news?id=d973092747c5ab174d35d1df42a960ee3659bcff3437e46029e44d8c3118d114",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Discover Johnson & Johnson (JNJ): a top dividend stock with a 2.10% yield, 7.68% growth history, and high profitability rating. A balanced pick for reliable income.",
                "category": "company",
                "datetime": 1784803229,
                "headline": "Johnson & Johnson (NYSE:JNJ) Is a Top Dividend Quality Stock for Reliable Income"
              },
              {
                "id": 140991883,
                "url": "https://finnhub.io/api/news?id=479e5cf7910e61ab90a739d2fa57deccce903267d8591b07b6a50d5c2b4d0fa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization makes Johnson & Johnson a new competitor in U.S. soft‑tissue robotic surgery, potentially reshaping procedure choices for hospitals and surgeons that have long relied on...",
                "category": "company",
                "datetime": 1784798020,
                "headline": "Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?"
              }
            ],
            "raw_source": [
              {
                "id": 141037166,
                "url": "https://finnhub.io/api/news?id=47fde8cf6cf537b615efc481300dac44cba78e8550ad22fd114ca61fd3aafdec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]",
                "category": "company",
                "datetime": 1785185861,
                "headline": "Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?"
              },
              {
                "id": 141037167,
                "url": "https://finnhub.io/api/news?id=77af2bd8392e02f9187a98e53b9e7e0817d0974616c0cf27aaa3425dad8caed4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ap",
                "category": "company",
                "datetime": 1785182460,
                "headline": "Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer"
              },
              {
                "id": 141037135,
                "url": "https://finnhub.io/api/news?id=f039384443066be35bc6ced345a619fa1e6911431bbd02d74d2a8573ae541097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.",
                "category": "company",
                "datetime": 1785182092,
                "headline": "The Engine Behind ABBV Stock Has Real Parts"
              },
              {
                "id": 141037136,
                "url": "https://finnhub.io/api/news?id=1962630925adf572941ee3d09545871641e85445ce685d06cecba1d3bddbddb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.",
                "category": "company",
                "datetime": 1785180480,
                "headline": "UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141035128,
                "url": "https://finnhub.io/api/news?id=b58d464b27d7f23f9a829bbedeecdcfeaa6027ba0087c79c62c1a13671ff8765",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.",
                "category": "company",
                "datetime": 1785170160,
                "headline": "Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?"
              },
              {
                "id": 141035129,
                "url": "https://finnhub.io/api/news?id=c92ef4a473af545abf93085c0feb833d345113b7ee6e12a65912c65c41f0d0ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.",
                "category": "company",
                "datetime": 1785167220,
                "headline": "J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?"
              },
              {
                "id": 141033665,
                "url": "https://finnhub.io/api/news?id=226e97769226d352193ee468abc933e80443ec0634412daea81166b5b2cba6ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.",
                "category": "company",
                "datetime": 1785166830,
                "headline": "Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck"
              },
              {
                "id": 141032898,
                "url": "https://finnhub.io/api/news?id=6615fc66077e5d2d0c4d94d8221ea056226840814fa58f92010b88792e506262",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]",
                "category": "company",
                "datetime": 1785158883,
                "headline": "President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling"
              },
              {
                "id": 141032152,
                "url": "https://finnhub.io/api/news?id=c9cdc9b27f60fb3ee8e170927c5226a3a2b0d43646e685a4c0755d0565d70fa0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.",
                "category": "company",
                "datetime": 1785145260,
                "headline": "Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson"
              },
              {
                "id": 141031076,
                "url": "https://finnhub.io/api/news?id=62173fbda2301693a92f3d5da56390b4ea3db8e08c290385b475eabf6e1d5a7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.",
                "category": "company",
                "datetime": 1785135053,
                "headline": "Johnson & Johnson Now Leads Its Pitch With An Oncology Bet"
              },
              {
                "id": 141030812,
                "url": "https://finnhub.io/api/news?id=4b6e6d93296faed73bb2ef8ae9464545cf430aa9aee7768bdfe0f63f83fd0474",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232218380/image_2232218380.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Veradermics is well-funded through the expected FDA submission in early 2027 and potential commercial launch in 2028. See why MANE stock is a Hold.",
                "category": "company",
                "datetime": 1785119424,
                "headline": "Veradermics: Wait For The Post-Lockup, But Buy Before The Roll-Up"
              },
              {
                "id": 141026817,
                "url": "https://finnhub.io/api/news?id=e83e5a8e0a8629b76fe9443999860bb064d143c549fc24404d45d48ca34ca42e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stopping work at 62 while waiting for a bigger Social Security check sounds clean on paper, but the math gets complicated fast when a portfolio has to carry the entire household for years. Here is how much capital different yield strategies actually require, and which tradeoffs could quietly wreck the plan.",
                "category": "company",
                "datetime": 1785095554,
                "headline": "A $550,000 Portfolio That Quietly Pays a 62-Year-Old $3,400 a Month Until Social Security Kicks In"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141025855,
                "url": "https://finnhub.io/api/news?id=b4c5c273ea2ff189dfa396040dbf45b5f6cab27bbecbd89f4a3b4abb399534a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.",
                "category": "company",
                "datetime": 1785084681,
                "headline": "How to Build $4,000 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141023888,
                "url": "https://finnhub.io/api/news?id=0e7c8b9ce48492e0870a97c7e8778cdbf2f0ff180e2b5db500c5b8c844969d64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Both have very promising futures.",
                "category": "company",
                "datetime": 1785060420,
                "headline": "Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?"
              },
              {
                "id": 141023596,
                "url": "https://finnhub.io/api/news?id=aa93f6b650dcda9f8826f3f7390c5a02e2548ec74e81335b1ebe7541cf3f7d9d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Track this week’s market catalysts: Big Tech earnings, Fed rate decision, and core PCE inflation data—plus IPOs and key reports.",
                "category": "company",
                "datetime": 1785048021,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141021018,
                "url": "https://finnhub.io/api/news?id=3a21c791543218a3dcf776fa77cd33387f0d0b3f1fefebf9bce8f21d87cc57f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $2 million retirement portfolio can generate wildly different income streams depending on where you put it, and choosing the wrong tier does not just leave money on the table. It can quietly eat your principal alive while you think you are getting rich.",
                "category": "company",
                "datetime": 1785023295,
                "headline": "The $2 Million Retirement Mistake: Confusing Yield With Income You Can Actually Spend"
              },
              {
                "id": 141020270,
                "url": "https://finnhub.io/api/news?id=7f9ee9e9891472b3ca8091ba21bc032ee3ef7180d7a8dcfe3d6ab7139cd24513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.",
                "category": "company",
                "datetime": 1785019617,
                "headline": "Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?"
              },
              {
                "id": 141016864,
                "url": "https://finnhub.io/api/news?id=02a7054929fccd13b94135fcc42ef9eaf195056dd9ae3898a266d92a88bdf526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.",
                "category": "company",
                "datetime": 1784989802,
                "headline": "Johnson & Johnson Is Becoming A Narrower Company Than You Bought"
              },
              {
                "id": 141015956,
                "url": "https://finnhub.io/api/news?id=30c853daab5af443ab8a0c8862a8b56eabb48569926bf56471b440d71080bbab",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/attachment/image/1d2aed9fc253168620c030b0153c6b23.png?io=w640",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Wall Street Breakfast recap: stocks slide on oil surge, tech earnings, tariffs and Middle East tensions.",
                "category": "company",
                "datetime": 1784970358,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 141015072,
                "url": "https://finnhub.io/api/news?id=16830e1d8b90f829bbd5e5977c2ddc14c197164f44230010d0e383c3a2102e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson (NYSE:JNJ)’s stock is up by 15%. As the shares struggled in […]",
                "category": "company",
                "datetime": 1784966368,
                "headline": "Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next"
              },
              {
                "id": 141012890,
                "url": "https://finnhub.io/api/news?id=5c10bc0162533a4bf0bf35e19474439a697677179f95faaee57891b759074e87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stripe is reportedly circling PayPal in a deal that could end a frustrating run for the fintech giant, but is it a good enough deal?",
                "category": "company",
                "datetime": 1784943415,
                "headline": "Does PayPal Have a Buyer?"
              },
              {
                "id": 141012101,
                "url": "https://finnhub.io/api/news?id=4e1e23cf08396f986f5b9a6bb8cb7b76eaa05c1892763d61ed11183134d2e9c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called \"safer parts of the market.\"\"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well.\"The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.",
                "category": "company",
                "datetime": 1784931586,
                "headline": "Nasdaq lags on angst over AI spending ahead of earnings reports"
              },
              {
                "id": 141012125,
                "url": "https://finnhub.io/api/news?id=df9ddbba648df52ff017922094bd25e71324c6ce3d875d9a4358040044d82db0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...",
                "category": "company",
                "datetime": 1784931178,
                "headline": "Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma"
              },
              {
                "id": 141012126,
                "url": "https://finnhub.io/api/news?id=a6b3d3b8c03098c58b1346b2c6d34207a883c82b0665d95e74987a6c7995738c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing a Social Security check with dividend income sounds straightforward until you realize the yield you chase changes the capital required by more than a million dollars. The tier you pick carries tradeoffs most income investors only discover after the fact.",
                "category": "company",
                "datetime": 1784931123,
                "headline": "How Much Do You Need Invested to Match the Maximum Social Security Benefit With Dividends?"
              },
              {
                "id": 141012380,
                "url": "https://finnhub.io/api/news?id=1049f08222cb659a27f732cbe315d0815331fce9aae8adcb12d874d1f0f61c7c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262233592/image_2262233592.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.",
                "category": "company",
                "datetime": 1784924522,
                "headline": "Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins"
              },
              {
                "id": 141008873,
                "url": "https://finnhub.io/api/news?id=0a485f1fa08b431da2d3ffb0109a55c9e9c924b2f7213f2766d5efe23d30f2e8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Friday.",
                "category": "company",
                "datetime": 1784920204,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141007083,
                "url": "https://finnhub.io/api/news?id=4997b4df2c1439dc08aeccb21803747beb7d511fe544df611dff9e6b9aa18a2c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1784911204,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 141007741,
                "url": "https://finnhub.io/api/news?id=d7584817bec7c3ef4b0c8862f86610832afabe80d1badde5236e6e6e58315775",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.",
                "category": "company",
                "datetime": 1784906100,
                "headline": "Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher"
              },
              {
                "id": 141007742,
                "url": "https://finnhub.io/api/news?id=1a4bd9a8e927b4e383f7109324d5417675ca77a48f556859be0ac2e47c6b2f72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.",
                "category": "company",
                "datetime": 1784903700,
                "headline": "J&J's Innovative Medicine Unit Proves Its Resilience in Q2"
              },
              {
                "id": 141006317,
                "url": "https://finnhub.io/api/news?id=12cb6ad467a619cc4b1dda5d74bcfebe305f49b91f339fbe7e6c8b6c00d8a48e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.",
                "category": "company",
                "datetime": 1784903700,
                "headline": "This \"Boring\" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It"
              },
              {
                "id": 141006418,
                "url": "https://finnhub.io/api/news?id=140a641b3b970824f2d295f86d2c74ac566785dc1512b72217bcc54a2b304405",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...",
                "category": "company",
                "datetime": 1784899863,
                "headline": "FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System"
              },
              {
                "id": 141005276,
                "url": "https://finnhub.io/api/news?id=fce891feb90878c9b568365dc8ab8155bd45866a90ca9d2b3a5d6fc1f72863eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.",
                "category": "company",
                "datetime": 1784897252,
                "headline": "Intuitive Surgical Stock Is On Sale, But Is The Growth Story Changing?"
              },
              {
                "id": 141005156,
                "url": "https://finnhub.io/api/news?id=ffd2c2a9406766dbc8d7cff9d7e264aace42953ab8d198bc2b8e577cddd077d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.",
                "category": "company",
                "datetime": 1784896215,
                "headline": "3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives"
              },
              {
                "id": 141005278,
                "url": "https://finnhub.io/api/news?id=101d57aad953e5f98a330ef27d7ba5c285a1af9a27e27bfc8b6dd584d78b6aa2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]",
                "category": "company",
                "datetime": 1784895731,
                "headline": "Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse"
              },
              {
                "id": 141005066,
                "url": "https://finnhub.io/api/news?id=9dacf9259e58fd1221029fce5064498f33c276a99b93ce347dbff82166b669fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Legend Biotech Corporation stock: strong Carvykti demand lifts Q2 sales; LB2501 CAR-T shows Phase 1 promise. Click for this LEGN update.",
                "category": "company",
                "datetime": 1784886309,
                "headline": "Legend Biotech: Why I'm Ready To Go Long Again"
              },
              {
                "id": 141006409,
                "url": "https://finnhub.io/api/news?id=e1ce78c5a51a944eb62e6a59e63cc3b2a92e6e9f3dc15efba3b36dc07aba88e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.",
                "category": "company",
                "datetime": 1784883600,
                "headline": "Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma"
              },
              {
                "id": 141001671,
                "url": "https://finnhub.io/api/news?id=2b3d8469f528d79fb00654c130f687ab423e66a83b114c1d4335fd3db9a5f390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.",
                "category": "company",
                "datetime": 1784833972,
                "headline": "J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock."
              },
              {
                "id": 140997116,
                "url": "https://finnhub.io/api/news?id=bc6828dc888b16a18d4634c6b054cfddda83b8c9bd63e85c8a711b2f5a305ff4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784833803,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 140997478,
                "url": "https://finnhub.io/api/news?id=1de5038ef073af3ed66423bedc4fc046766610b7dfdc096d519b53d8bc890542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.",
                "category": "company",
                "datetime": 1784827913,
                "headline": "Best Monthly Dividend ETFs for Consistent Income"
              },
              {
                "id": 140995615,
                "url": "https://finnhub.io/api/news?id=2b1f0452b3a057ed6a9cc36b34e4ba342fc311f608df0b5acc4cf4ca752eee72",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784824804,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140998074,
                "url": "https://finnhub.io/api/news?id=3c44c743d1bcf2a3d934bc59f7bc8777ff1351e9911e6554c104a544377e0eb8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Woman-Touching-Stomach-Painful-Suffering.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.",
                "category": "company",
                "datetime": 1784815607,
                "headline": "Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2"
              },
              {
                "id": 140996248,
                "url": "https://finnhub.io/api/news?id=d79a92d059cad5703142a835ff2763e844d94c47b3c52e8a5be7f5bb39a5e428",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Zevra Therapeutics jumps on FDA Orange Book patent exclusivity to 2041; profitability, cash-rich balance sheet, celiprolol pipeline. Click for more on ZVRA stock.",
                "category": "company",
                "datetime": 1784815020,
                "headline": "Zevra Therapeutics: Worthy Of An Initial Holding"
              },
              {
                "id": 140994646,
                "url": "https://finnhub.io/api/news?id=f128455069eee81b95530f62b343bf3bb525c652a351fbc7f991a20272c72a2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.",
                "category": "company",
                "datetime": 1784813100,
                "headline": "ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook"
              },
              {
                "id": 140993342,
                "url": "https://finnhub.io/api/news?id=3e5112537701d1d11c6dcbe27975b37a9f64ba94d81f255b1b487843afdf4fe0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY® + pomalidomide in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.1 The",
                "category": "company",
                "datetime": 1784809800,
                "headline": "TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma"
              },
              {
                "id": 140994622,
                "url": "https://finnhub.io/api/news?id=907f28abe35f979441ffb5b0eba0ee9edf990499605ef84e64f776b74c770b7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks have spent months shrugging off geopolitical shocks, businesses are transforming to prepare for a more volatile world.",
                "category": "company",
                "datetime": 1784804100,
                "headline": "Trump’s Iran War and Tariffs Are Changing Corporate Strategies"
              },
              {
                "id": 140993227,
                "url": "https://finnhub.io/api/news?id=ce7062302e8402a96306c8c45637bf7a00ed2e04d6ff96634c948fe414e5f316",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While stocks shrug off oil shocks and global tariff turmoil, businesses are transforming to prepare for a more volatile world.",
                "category": "company",
                "datetime": 1784804100,
                "headline": "Markets Seem Desensitized to Trump’s Iran War and Tariffs but Companies Are Changing in Fundamental Ways"
              },
              {
                "id": 140992107,
                "url": "https://finnhub.io/api/news?id=d973092747c5ab174d35d1df42a960ee3659bcff3437e46029e44d8c3118d114",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Discover Johnson & Johnson (JNJ): a top dividend stock with a 2.10% yield, 7.68% growth history, and high profitability rating. A balanced pick for reliable income.",
                "category": "company",
                "datetime": 1784803229,
                "headline": "Johnson & Johnson (NYSE:JNJ) Is a Top Dividend Quality Stock for Reliable Income"
              },
              {
                "id": 140991883,
                "url": "https://finnhub.io/api/news?id=479e5cf7910e61ab90a739d2fa57deccce903267d8591b07b6a50d5c2b4d0fa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization makes Johnson & Johnson a new competitor in U.S. soft‑tissue robotic surgery, potentially reshaping procedure choices for hospitals and surgeons that have long relied on...",
                "category": "company",
                "datetime": 1784798020,
                "headline": "Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?"
              },
              {
                "id": 140993894,
                "url": "https://finnhub.io/api/news?id=cc6c61fe6d1e1a1fae49aa5ff7dec69b7a05992a9c5c49f6f835e15d6dd2b42d",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI®",
                "category": "company",
                "datetime": 1784795995,
                "headline": "Johnson & Johnson Announces Topline Results From Phase 3 MonumenTAL-6 Study Evaluating TECVAYLI + TALVEY In Adult Patients With Multiple Myeloma; Study Demonstrated Statistically Significant And Clinically Meaningful Improvements In Progression-Free Survival And Overall Survival"
              },
              {
                "id": 140997606,
                "url": "https://finnhub.io/api/news?id=ce69505dde9c2aa7483984a1a158e4307eff9fe773f140fbefc671155f13219d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.",
                "category": "company",
                "datetime": 1784779260,
                "headline": "Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts"
              },
              {
                "id": 140990421,
                "url": "https://finnhub.io/api/news?id=047e681965bfd08426680193b957bca32d3e9102ba561524161f9a1d4deeb9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.",
                "category": "company",
                "datetime": 1784777466,
                "headline": "Why Did PEGA, ISRG, MCD Stocks Plunge To 52-Week Lows Today?"
              },
              {
                "id": 140990422,
                "url": "https://finnhub.io/api/news?id=81fd8a8980d831085dda3c60ed3a64b3c1537b74a859dad13bb7fc26bc5d0a01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.",
                "category": "company",
                "datetime": 1784752362,
                "headline": "Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today"
              },
              {
                "id": 140984721,
                "url": "https://finnhub.io/api/news?id=a13c31f2ca7a17cbdb44673ee3c85c3060b31c53559d522b6d7a2d88928cab6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.",
                "category": "company",
                "datetime": 1784738350,
                "headline": "J&J MedTech jumps into surgical robot game as OTTAVA secures FDA nod"
              },
              {
                "id": 140984722,
                "url": "https://finnhub.io/api/news?id=eb4380e4b81ff41df4f41f4d09a834efdf3a51fc5ecc7ebde526712ba4b692b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.",
                "category": "company",
                "datetime": 1784736300,
                "headline": "ISRG Growth Story Hinges on Da Vinci 5, Ion and Recurring Revenue"
              },
              {
                "id": 140984723,
                "url": "https://finnhub.io/api/news?id=b43dd450ad337f594f3885cf44a2dfe69b42d47cc6c24474b47251767859f188",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.",
                "category": "company",
                "datetime": 1784736240,
                "headline": "ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure"
              },
              {
                "id": 140984724,
                "url": "https://finnhub.io/api/news?id=b815e8f186230069c844603013fcb9e7af4852d0d473a0021673777909f3f8df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.",
                "category": "company",
                "datetime": 1784736180,
                "headline": "Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise"
              },
              {
                "id": 140984725,
                "url": "https://finnhub.io/api/news?id=b5b7b606303ea11c39254d66783410e7e0eab7130a80773a858aa8724f3ea01b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
                "category": "company",
                "datetime": 1784735103,
                "headline": "Are You Looking for a High-Growth Dividend Stock?"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140983038,
                "url": "https://finnhub.io/api/news?id=af342790192e7316a463a5090eb0e7bb7be2a834da8d153ed2ff10848da12fdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1784725205,
                "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140981795,
                "url": "https://finnhub.io/api/news?id=3ba1d70465d2d304236b3d43b6d8d900ae16e7215652ec563e417a5d0159be3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Connecticut Innovations (CI), the state's strategic venture capital arm, today announced a record-breaking fiscal year, generating $66.5 million in cash proceeds from a series of landmark portfolio exits and a combined $76.1 million from all investment activities. CI invested $59.3 million in 75 early-stage companies and venture funds during the fiscal year ending June 30, 2026, with those deals leveraging an additional $1.2 billion in outside capital.",
                "category": "company",
                "datetime": 1784725200,
                "headline": "Connecticut Innovations Generates Record $66.5 Million in Proceeds in FY2026"
              },
              {
                "id": 140981796,
                "url": "https://finnhub.io/api/news?id=51341f17d0269da48d19702712dcc37965750ed345119a22ad1103ff48ab6628",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.",
                "category": "company",
                "datetime": 1784723760,
                "headline": "Can LQDA's Differentiated PAH Strategy Drive Long-Term Growth?"
              },
              {
                "id": 140983039,
                "url": "https://finnhub.io/api/news?id=3af468cbae481110ca71e4daaf0b3848b3cb86aca78ef879769dc79ed3241107",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery ‌device, as the healthcare conglomerate enters the soft-tissue robotic surgery market.  The decision ‌marks a key step for J&J's medtech business that had been seeking to compete in the robotic-assisted ​surgery market, currently dominated by Intuitive Surgical's da Vinci system.  Medtronic's Hugo robot was also approved last year.",
                "category": "company",
                "datetime": 1784719310,
                "headline": "J&J enters US robotic surgery market after device gets marketing authorization"
              },
              {
                "id": 140980995,
                "url": "https://finnhub.io/api/news?id=9f31bc6f86a6cc83697b8caa1dad493b56ddbcc8e5c0f9a1cf4cc9e68c195b86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 22, 2026--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world’s first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fun",
                "category": "company",
                "datetime": 1784718000,
                "headline": "Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System"
              },
              {
                "id": 140984726,
                "url": "https://finnhub.io/api/news?id=b007f8436b6a97262a650356dc317c7c77e8620d53a9fd7822da3e4e79f99ca5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While Johnson & Johnson will go head to head with Intuitive in the U.S., analysts questioned whether its robotic surgery system will take meaningful share from the market leader.",
                "category": "company",
                "datetime": 1784717586,
                "headline": "J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive"
              },
              {
                "id": 140980996,
                "url": "https://finnhub.io/api/news?id=6402c92c6150025f885e084202c1bab0532dca40ce6b9079c4673f8507f71fed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "WIXOM, Mich., July 22, 2026--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Rockwell Medical Advances Quality and Regulatory Leadership"
              },
              {
                "id": 140981615,
                "url": "https://finnhub.io/api/news?id=2f9c9575c82c8b7e73a95c3d96d13cfe3411bbcca5359a37a0a5341a439fca83",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196897625/image_2196897625.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "The Voya Global Equity Dividend and Premium Opportunity Fund blends high current income with equity exposure. Read more on IGD CEF here.",
                "category": "company",
                "datetime": 1784713300,
                "headline": "IGD: Attractive Yield, But Discount Is Smaller Than Normal"
              },
              {
                "id": 140987702,
                "url": "https://finnhub.io/api/news?id=136b167322d2eca0a36f07982005e78be1cd0a6810384bcceb18d98c3778b21a",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy,",
                "category": "company",
                "datetime": 1784704603,
                "headline": "Johnson & Johnson Receives FDA De Novo Authorization For Its OTTAVA Robotic Surgical System"
              },
              {
                "id": 140978430,
                "url": "https://finnhub.io/api/news?id=11bf2dccdb7048d386cdf69f80cd417cbba115f2f144d149c1660b23596f7d91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the stock’s current payout profile and upcoming key dates. See our latest analysis for Johnson & Johnson. The latest dividend announcement comes shortly after Johnson & Johnson reported second quarter 2026 results, raised full year sales guidance to US$100.8b to US$101.4b, and secured FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF...",
                "category": "company",
                "datetime": 1784679524,
                "headline": "Johnson & Johnson (JNJ) Raised Its Dividend, Where Does Fair Value Sit?"
              },
              {
                "id": 140983640,
                "url": "https://finnhub.io/api/news?id=be232ffd5f24c370e540bfb5a76468eb8bccb5950f42060db323284f869a8881",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/22/Washington-D-c---Usa---February-4--2025-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.",
                "category": "company",
                "datetime": 1784671990,
                "headline": "Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140974912,
                "url": "https://finnhub.io/api/news?id=bbdead80568b813174817288369cedcdbc1558cbe69a3fa5d808987e69a9b82d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.",
                "category": "company",
                "datetime": 1784660157,
                "headline": "Why BSX Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 140974913,
                "url": "https://finnhub.io/api/news?id=aa203e7f28d79433427fb12950820e559672ed5b69c0e2a20f702bef68a97fcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.",
                "category": "company",
                "datetime": 1784659383,
                "headline": "ISRG Stock: The Math Hidden In Its Price"
              },
              {
                "id": 140974897,
                "url": "https://finnhub.io/api/news?id=4527046ec46f67e07022ec64ce36d30476070db35309a16067f492a6176d2f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.",
                "category": "company",
                "datetime": 1784658705,
                "headline": "AbbVie Stock Zigs When The Market Zags"
              },
              {
                "id": 140973269,
                "url": "https://finnhub.io/api/news?id=5ebe2d0d061ee992e8b81faa547161aa156188af914c5d603050ed0d9e91fad7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the market growth.New York, U",
                "category": "company",
                "datetime": 1784653200,
                "headline": "Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight"
              },
              {
                "id": 140972633,
                "url": "https://finnhub.io/api/news?id=84e014f7731953bd7829bfc0ad7dc079f0d6754d329df7ff4d1a508919d5026f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1784652003,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 140971473,
                "url": "https://finnhub.io/api/news?id=b128ec3cee87a063d5a49088b82bbd71d52e3598fc8695ab7550deeaf60443c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?",
                "category": "company",
                "datetime": 1784646039,
                "headline": "Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories"
              },
              {
                "id": 140971589,
                "url": "https://finnhub.io/api/news?id=6e9cb60560ec50a9dc2a5e4ff31cabd7f9a7b79b6c11da15cec0d4eda37c4146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.",
                "category": "company",
                "datetime": 1784644680,
                "headline": "HALO Inks Deal With INCY to Support Cancer Therapy Development"
              },
              {
                "id": 140971590,
                "url": "https://finnhub.io/api/news?id=bf3be5c4aadc5bb0bd972cfa359c3c94ff40f39adcdba75fb3284460badcd206",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Seventy companies have raised their dividends through every recession and rate shock for at least a quarter century, but a bruising few quarters for some of NOBL's most-watched names put that unbroken record under real pressure heading into mid-2026.",
                "category": "company",
                "datetime": 1784642575,
                "headline": "70 Dividend Aristocrats Face Their Mid-2026 Test: NOBL’s 2% Yield Under Pressure"
              },
              {
                "id": 140970443,
                "url": "https://finnhub.io/api/news?id=c16cb7492dd2fe661f9ecf0214d921f3c009cf7fdd70e16f5dd383f871bc466f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligence into hospital systems across the United States, the United Kingdom, and beyond.",
                "category": "company",
                "datetime": 1784638800,
                "headline": "MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth"
              },
              {
                "id": 140968909,
                "url": "https://finnhub.io/api/news?id=66900d2496d7d62427385dac2b48e61ca822d10f397ca17194674abb3f1a3a03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson, Lam Research and Seagate lead today's analyst picks as strong results, AI demand and growth outlooks drive the latest research.",
                "category": "company",
                "datetime": 1784619540,
                "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, Lam Research, Seagate, KVH Industries and Dawson Geophysical"
              },
              {
                "id": 140967453,
                "url": "https://finnhub.io/api/news?id=71d152747a124f650547e49559e52976f82ea03fbbd25e53f37829d152156f70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.",
                "category": "company",
                "datetime": 1784599220,
                "headline": "Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run"
              },
              {
                "id": 140964880,
                "url": "https://finnhub.io/api/news?id=12a8abdbc76bf7f5d75a741fcb8bf92b1169e627404cdd9748c5e4427653cfaf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read what's driving outlook.",
                "category": "company",
                "datetime": 1784578140,
                "headline": "Top Analyst Reports for Johnson & Johnson, Lam Research & Seagate"
              },
              {
                "id": 140963421,
                "url": "https://finnhub.io/api/news?id=6ea0dd033658292f48582a592a40caa31066d357172a543dd20d199c2861cc74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.",
                "category": "company",
                "datetime": 1784574905,
                "headline": "The Robot Maker's Paradox"
              },
              {
                "id": 140962978,
                "url": "https://finnhub.io/api/news?id=02b2e30e4b5a8015da142e1b9a1f892637cc927d311f40cc472a5668f9bca33d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1784574604,
                "headline": "Stay informed with the top movers within the dow jones index on Monday."
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140963423,
                "url": "https://finnhub.io/api/news?id=26047126ae59bd8c4eb72c217ec847dd194744894cd020aa98db1bbb6da3a19e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.",
                "category": "company",
                "datetime": 1784571665,
                "headline": "What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?"
              },
              {
                "id": 140963424,
                "url": "https://finnhub.io/api/news?id=589a1dde19072b6d106740e598d7398a3c273b730e0ffb276308b41b42040853",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer took a bullish stance on Alibaba despite its brutal year-to-date slide, pairing the call with two steady compounders he thinks belong in every long-term portfolio. Here is what he told one caller sitting on a sizable BABA position.",
                "category": "company",
                "datetime": 1784570231,
                "headline": "Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD"
              },
              {
                "id": 140971579,
                "url": "https://finnhub.io/api/news?id=b34dab5f1189ce264bb943480be0297ade22fedb65a81a841f4d005657c7a48b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While AI stocks correct, Johnson & Johnson, Altria, Coca-Cola, JPMorgan, and Apple are quietly trading near 52-week or all-time highs ahead of earnings.",
                "category": "company",
                "datetime": 1784561100,
                "headline": "5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama"
              },
              {
                "id": 140960594,
                "url": "https://finnhub.io/api/news?id=b6dc2875bc5307f0ba48199fbd747c6354cd7ce2ee06b8136a7e109730aa2ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?",
                "category": "company",
                "datetime": 1784551980,
                "headline": "Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?"
              },
              {
                "id": 140959509,
                "url": "https://finnhub.io/api/news?id=c8528b8311704302ec45b4ffa65ff0f68ee49d76d3993cfcb752857c60ab52b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LQDA, BILL and Colgate-Palmolive highlight recent Zacks picks as multiple portfolios outperformed or posted strong stock gains despite market volatility.",
                "category": "company",
                "datetime": 1784550840,
                "headline": "Beat the Market the Zacks Way: Liquidia, BILL, Colgate-Palmolive in Focus"
              },
              {
                "id": 140959510,
                "url": "https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784549820,
                "headline": "Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."
              },
              {
                "id": 140958951,
                "url": "https://finnhub.io/api/news?id=5ed9acc8832a619e0dcafb8eca77d97a1e2404577fca62c7969d2a1bbc22ad55",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "ImmunityBio (IBRX) cautious buy: Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.",
                "category": "company",
                "datetime": 1784536225,
                "headline": "ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)"
              },
              {
                "id": 140958130,
                "url": "https://finnhub.io/api/news?id=ec6706319150549ddafa63e0a3db84a31d57f725ac1deda3893c213e428ab5e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Despite its enticing dividend yield and relatively attractive valuation, J&J Snack Foods' (JJSF) stock may represent a value trap.",
                "category": "company",
                "datetime": 1784534400,
                "headline": "Bear of the Day: J&J Snack Foods (JJSF)"
              },
              {
                "id": 140957651,
                "url": "https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784527200,
                "headline": "What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."
              },
              {
                "id": 140955522,
                "url": "https://finnhub.io/api/news?id=8d88b130ffa95c1632bba1a2a2e600b109439fdb1e85c0c8ffa6f37540cd5258",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J has more than 28 sources of blockbuster revenue.",
                "category": "company",
                "datetime": 1784500200,
                "headline": "Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?"
              },
              {
                "id": 140954711,
                "url": "https://finnhub.io/api/news?id=bd7f9275f6da066da0e062bbc8c0c2967aae456c9c00c3c32cd0ef0849b285c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "They can help stabilize your portfolio in these otherwise volatile times.",
                "category": "company",
                "datetime": 1784492400,
                "headline": "My 2 Favorite Dividend Kings to Buy Right Now"
              },
              {
                "id": 140953052,
                "url": "https://finnhub.io/api/news?id=67eeee0773b2fcf0a7f7695994ba789e51fa6c55cddd961ffbccaed06e0cc8b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...",
                "category": "company",
                "datetime": 1784477270,
                "headline": "Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device"
              },
              {
                "id": 140951671,
                "url": "https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.",
                "category": "company",
                "datetime": 1784467858,
                "headline": "3 Biggest Pharma Giants: Buy, Sell or Hold?"
              },
              {
                "id": 140951727,
                "url": "https://finnhub.io/api/news?id=4ae5fefce3d887eea60615731dbad10a3cf82c75257323d81f2e4c81c3a0cde3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.",
                "category": "company",
                "datetime": 1784466389,
                "headline": "Would You Rather Earn $55,000 Today or $110,000 in 20 Years?"
              },
              {
                "id": 140951073,
                "url": "https://finnhub.io/api/news?id=fafc6aeb110fdd02064f73a91ea365091609ea30e4fb379d6dcb9508affe1c6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the biggest dividend check they can find today, but that instinct quietly sabotages the income they could be collecting a decade from now. The math behind a smarter approach is almost offensively simple once you see it.",
                "category": "company",
                "datetime": 1784458843,
                "headline": "From a $38,000 Income to $84,000 Without Investing Another Dollar"
              },
              {
                "id": 140950551,
                "url": "https://finnhub.io/api/news?id=f01b55cce75788117c7e394aa1e666da2acbea913eccbbe07be2af1e72923c65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Headline inflation keeps rising faster than Social Security adjustments, quietly shrinking what retirement actually buys. A small, dedicated portfolio sleeve could fund those annual increases entirely from income, but the tier you choose changes everything about how much capital you actually need.",
                "category": "company",
                "datetime": 1784452337,
                "headline": "The Portfolio That Lets You Ignore Inflation"
              },
              {
                "id": 140943803,
                "url": "https://finnhub.io/api/news?id=0dc2c819466c7138315ffa76be796026e4c9152e78e0aa2ecd3903decb24e813",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.",
                "category": "company",
                "datetime": 1784387281,
                "headline": "The Portfolio That Gives You a $2,000 Raise Every Year"
              },
              {
                "id": 140943075,
                "url": "https://finnhub.io/api/news?id=967d9cb8efa721530bf134eb3b72fb54af112a8dce5b14647ab21b605e484810",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.",
                "category": "company",
                "datetime": 1784379647,
                "headline": "The Portfolio That Lets You Cruise Through the News, Unbothered"
              },
              {
                "id": 140943050,
                "url": "https://finnhub.io/api/news?id=b6726c67b6d318f590ea801e8e23e38a41d664def7724f009c1732cc043834e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.",
                "category": "company",
                "datetime": 1784376045,
                "headline": "3 Dividend Stocks That Have Survived Every Market Crash in July"
              },
              {
                "id": 140942415,
                "url": "https://finnhub.io/api/news?id=c189e19fb9e0837e2ced094a748f8a447c86c96f6cd670336ac539cab7f21005",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Lifelong learning sounds like a noble habit until you price it out across decades and realize it behaves more like a recurring expense than a one-time splurge. The portfolio that funds it may look nothing like the obvious choice.",
                "category": "company",
                "datetime": 1784373097,
                "headline": "Here’s the Funding It Takes to Keep Learning Forever"
              },
              {
                "id": 140951072,
                "url": "https://finnhub.io/api/news?id=73534d700060689b3f3e12bb0a8fd766db23bf8c5f3b1546e2cec50941fb3bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.",
                "category": "company",
                "datetime": 1784372400,
                "headline": "MarketBeat Week in Review – 07/13- 07/17"
              },
              {
                "id": 140939403,
                "url": "https://finnhub.io/api/news?id=57d40fe7bb5c8aac6f79be0256a9f813474876b809b4a24f9b6e6987567d036e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DIVO's covered-call strategy looks solid on paper, but two macro forces are quietly working against its monthly payouts in ways most income investors overlook. Here is what the options chain and the Treasury market are signaling right now.",
                "category": "company",
                "datetime": 1784333456,
                "headline": "If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income"
              },
              {
                "id": 140939163,
                "url": "https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.",
                "category": "company",
                "datetime": 1784328964,
                "headline": "Abbott Just Showed Its Growth Engine Has More Than One Cylinder"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140937906,
                "url": "https://finnhub.io/api/news?id=a0e0cf5d5229803aafd81bc10762576800986410f1c10defc757f88a1be078dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer named five blue-chip stocks the market punished after strong earnings, and he's betting that millions of investors and billions of dollars got it completely wrong.",
                "category": "company",
                "datetime": 1784322864,
                "headline": "Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks"
              },
              {
                "id": 140937907,
                "url": "https://finnhub.io/api/news?id=544c9a5b6ab515dd6fe654dd847834a8214c9a346b18b078ca02fbcb4330a814",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Cramer named specific sectors he's betting on for late 2026 while calling out two popular investments as traps that investors should exit now, regardless of where they bought in.",
                "category": "company",
                "datetime": 1784322800,
                "headline": "Jim Cramer Says Oracle Is “Going Down” and Avoid Every Liquor Stock. Here’s What He’d Buy Instead"
              },
              {
                "id": 140936306,
                "url": "https://finnhub.io/api/news?id=9379fd9a229dde89bca8d1d8f41d09e6f5b887ee5f712f95edadbe7a94d281c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DGRO's next index rebalance could quietly shift millions of dollars across healthcare and financials, and one overlooked holding sits at the center of the trade. Here is why the December reconstitution deserves more attention than investors are giving it.",
                "category": "company",
                "datetime": 1784315450,
                "headline": "DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch"
              },
              {
                "id": 140934459,
                "url": "https://finnhub.io/api/news?id=a2ee62a66c63a946d94c3e6beb499c40b3125181a2923f5fa2fc732d6e9e4955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.",
                "category": "company",
                "datetime": 1784307459,
                "headline": "VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way"
              },
              {
                "id": 140933705,
                "url": "https://finnhub.io/api/news?id=cf957e631b08afbc352ac0c9645261668019b12720ed7857cae855b3ae4f2250",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784306404,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140933340,
                "url": "https://finnhub.io/api/news?id=dc6646e28e14b3fdaff43894e8f7f8bbb22af0391c056fc946d02d9e5a21b04b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SPYI's 12% annualized payout looks generous until you check what two converging macro forces are quietly doing to the premium engine that funds it.",
                "category": "company",
                "datetime": 1784304654,
                "headline": "SPYI Investors: Watch These 2 Macro Factors Before the Next Distribution"
              },
              {
                "id": 140932972,
                "url": "https://finnhub.io/api/news?id=88bacf0e7e75d7ad7490cf737b97af9956511d5def5cdbef0d549d91e59d52d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four thousand dollars a month can cover a paid-off house, groceries, utilities, insurance, and modest travel in many parts of the country. It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially ... Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?",
                "category": "company",
                "datetime": 1784302670,
                "headline": "Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?"
              },
              {
                "id": 140932973,
                "url": "https://finnhub.io/api/news?id=0504e442cf7f265bb43b0e44d54c0386af3ed0aa7fd4f592d362e90177bbdfa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.",
                "category": "company",
                "datetime": 1784298660,
                "headline": "J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why"
              },
              {
                "id": 140931435,
                "url": "https://finnhub.io/api/news?id=43bdff8a716708433fb4dc9ca77c1f32465999080349e9d6bee352b6884763f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.",
                "category": "company",
                "datetime": 1784295671,
                "headline": "Stock Market Today: Nasdaq Leads Indexes Down; SpaceX Slides As Flight Canceled (Live Coverage)"
              },
              {
                "id": 140931563,
                "url": "https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.",
                "category": "company",
                "datetime": 1784290654,
                "headline": "Can Abbott Stock Deliver on Its Second-Half Growth Promise?"
              },
              {
                "id": 140931564,
                "url": "https://finnhub.io/api/news?id=c1f3439f3f31bb5e63491154cf43bcb3dc1f5d6f47086643b3ecba50b2f29e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.",
                "category": "company",
                "datetime": 1784289180,
                "headline": "Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years"
              },
              {
                "id": 140930733,
                "url": "https://finnhub.io/api/news?id=2f16834b08c6c17f3fe26ebf1ea738c1f438efeb6aa48d5eb4eb3ba6a91c9cde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A portfolio that pays $27,000 a year in dividends sounds modest. Left alone for a little more than a decade of steady dividend growth, that same income stream can quietly grow toward $66,000 without a single additional dollar of savings. That is the basic appeal of dividend growth investing: the arithmetic of today’s yield matters, ... Growing an Income Tree: From $27,000 to $66,000",
                "category": "company",
                "datetime": 1784286034,
                "headline": "Growing an Income Tree: From $27,000 to $66,000"
              },
              {
                "id": 140934862,
                "url": "https://finnhub.io/api/news?id=9254cbc0007632f41e4f18a578ee59d8ca248cce6c424d6e754fd2559e0baa3e",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Guggenheim  analyst Vamil Divan   reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.",
                "category": "company",
                "datetime": 1784277291,
                "headline": "Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140934035,
                "url": "https://finnhub.io/api/news?id=582214e1504528124d4be9c4af6af3802955bcbb5b2ad89b6f8829dfea0ac010",
                "image": "https://image.cnbcfm.com/api/v1/image/108336317-5ED3-MM-A-BLOCK-071626.jpg?v=1784242037&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer talks going against the grain in the market.",
                "category": "company",
                "datetime": 1784231304,
                "headline": "Jim Cramer: It takes a lot of guts to disagree with the market about a stock after it reports"
              },
              {
                "id": 140924324,
                "url": "https://finnhub.io/api/news?id=d4761d29e079ca2623b2595a2c5f2d57d077d95edfc51ae51e3148fa11e22d4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.",
                "category": "company",
                "datetime": 1784224421,
                "headline": "Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug"
              },
              {
                "id": 140922631,
                "url": "https://finnhub.io/api/news?id=7b429b088d655c237aac8342e677ff2e6a0d4bbbe45d0f80f410066bf2a7a864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those ... The Portfolio That Pays All Your Car Repairs For Life",
                "category": "company",
                "datetime": 1784224058,
                "headline": "The Portfolio That Pays All Your Car Repairs For Life"
              },
              {
                "id": 140924331,
                "url": "https://finnhub.io/api/news?id=2cccc71304a92dbf83c35d1711fa335b36545f9818f085bb547e2a190d5858bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.",
                "category": "company",
                "datetime": 1784222460,
                "headline": "Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?"
              },
              {
                "id": 140922632,
                "url": "https://finnhub.io/api/news?id=7c29be2f94767e0c8e1e1ad8878c710d0617b7fa7550c65b0b37d527287ef6d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Q2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.",
                "category": "company",
                "datetime": 1784218260,
                "headline": "Sector ETFs to Win on Q2 Earnings Growth Potential"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920971,
                "url": "https://finnhub.io/api/news?id=6eac034c6914e1faa4d3597b25972ecf5df2fdb6a0f3aad2a0291a50be75e185",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.",
                "category": "company",
                "datetime": 1784216700,
                "headline": "Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion"
              },
              {
                "id": 140920972,
                "url": "https://finnhub.io/api/news?id=599fd74550f7b98d365d009af33a716949e9a10cb0c48e26cf5ef5e8637d71f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's (JNJ) Innovative Medicine segment momentum is building into 2027, with the compa",
                "category": "company",
                "datetime": 1784215796,
                "headline": "Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says"
              },
              {
                "id": 140920973,
                "url": "https://finnhub.io/api/news?id=383c8a910d0b53a4d210ac7d5f3ecafa0dbf367b7fec681eb1bd02c4862d419b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784212620,
                "headline": "Why Abbott Stock Is Having Its Best Day in 24 Years"
              },
              {
                "id": 140925253,
                "url": "https://finnhub.io/api/news?id=7b55a75cfcff35bfaea03818a622a465035efd6daf3d0186d0f34f068e6f793e",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Raymond James  analyst Jayson Bedford   maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $258 to $265.",
                "category": "company",
                "datetime": 1784211124,
                "headline": "Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265"
              },
              {
                "id": 140920962,
                "url": "https://finnhub.io/api/news?id=2cec22579047e245108d6c96f0282da91db225b322b2727f1dee0c8a8a992058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.",
                "category": "company",
                "datetime": 1784210761,
                "headline": "Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140920975,
                "url": "https://finnhub.io/api/news?id=7c8ef675a3c6fa5fb020f15ac8b4d391cda0c47a701fbe8e4984298f9b1e9e13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.",
                "category": "company",
                "datetime": 1784210400,
                "headline": "Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat"
              },
              {
                "id": 140920976,
                "url": "https://finnhub.io/api/news?id=76bc23d4d790ded7e25ac854371641c9f43064d0b6f2a5978ce3830dc769912b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.",
                "category": "company",
                "datetime": 1784210345,
                "headline": "Why Abbott Stock Is Reimagining Its Future"
              },
              {
                "id": 140923118,
                "url": "https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.",
                "category": "company",
                "datetime": 1784208257,
                "headline": "UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919720,
                "url": "https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.",
                "category": "company",
                "datetime": 1784205864,
                "headline": "Why Is The Market Punishing JNJ Stock?"
              },
              {
                "id": 140925255,
                "url": "https://finnhub.io/api/news?id=a1e7a18b2666f804b907fee1ef3b62977722ec84865ee61dc95830e221a48894",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The reasons why RBC Capital Markets maintains its stock rating.",
                "category": "company",
                "datetime": 1784203897,
                "headline": "Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst"
              },
              {
                "id": 140919721,
                "url": "https://finnhub.io/api/news?id=6520635232f64f8347ba4e9dff3721065414e7b36bcf1950f94d2c6548cdc023",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 16, 2026--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all.",
                "category": "company",
                "datetime": 1784203860,
                "headline": "Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award"
              },
              {
                "id": 140919722,
                "url": "https://finnhub.io/api/news?id=bd3a772633121acf0452f10ab368b69a562e2c64a485ce99d79a2ec01db57828",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784203500,
                "headline": "Why Abbott Earnings Are Sending the Stock Higher"
              },
              {
                "id": 140919723,
                "url": "https://finnhub.io/api/news?id=de8e48f037f5c09136d811016bc9ddf198f5b74d438512b6dacad9fa099e2580",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "RAYNHAM, Mass., July 16, 2026--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.",
                "category": "company",
                "datetime": 1784203200,
                "headline": "DePuy Synthes Acquires Expanding Innovations™"
              },
              {
                "id": 140925256,
                "url": "https://finnhub.io/api/news?id=f6de372db2648d397e31f9942e51ccb26c3dd7374c1db33b16261b2fe74c1950",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "RBC Capital  analyst Shagun Singh   reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $287 price target.",
                "category": "company",
                "datetime": 1784199879,
                "headline": "RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $287 Price Target"
              },
              {
                "id": 140925257,
                "url": "https://finnhub.io/api/news?id=c4ad69c879606e9a3f256389df43bbfaf5fa9660a189217a14842a88cab536dc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "A report on July 15, 2026 shows that Representative Thomas Kean from New Jersey sale stock in Alphabet (NASDAQ:GOOGL), valued between $26,012 and $215,000. According to the July filing, the transaction occurred on June",
                "category": "company",
                "datetime": 1784199622,
                "headline": "New Jersey Rep. Thomas Kean Sold Over $26K Worth of Alphabet Stock: Here’s What You Should Know"
              },
              {
                "id": 140925258,
                "url": "https://finnhub.io/api/news?id=8bf525878cd1213d29b7dccd45b7fb5e3eb5eb5f9f5d242f48df0f4e450f5507",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $263 to $272.",
                "category": "company",
                "datetime": 1784199227,
                "headline": "Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $272"
              },
              {
                "id": 140918830,
                "url": "https://finnhub.io/api/news?id=b8067d2e125f2fadd902082d475fcb21d24467c27a57848a9d67cfeb5786361c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided ... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income",
                "category": "company",
                "datetime": 1784197760,
                "headline": "The Portfolio Blueprint for Building $20,000 a Month in Dividend Income"
              },
              {
                "id": 140922157,
                "url": "https://finnhub.io/api/news?id=386c0b9c1c3d9557d90a82f0a6e027a81e4638d8b6d3f8ba2779826e7a8c42f5",
                "image": "https://image.cnbcfm.com/api/v1/image/108335965-17842089721784208970-47198742640-1080pnbcnews.jpg?v=1784208971&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1784194960,
                "headline": "Cramer’s Mad Dash: Johnson & Johnson"
              },
              {
                "id": 140925259,
                "url": "https://finnhub.io/api/news?id=8e8ff9972320acf9872e5c5f441d391a77a1bf0345ca3e918d5ba001518be010",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $284 to $294.",
                "category": "company",
                "datetime": 1784193945,
                "headline": "Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $294"
              },
              {
                "id": 140925260,
                "url": "https://finnhub.io/api/news?id=014de1ad8e4e545a4a3f02e2d375594a5f01a2ee6dea5eaa486ec601be65e351",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.Expanding Innovations (EI) is a commercial-stage medical technology company",
                "category": "company",
                "datetime": 1784189685,
                "headline": "Johnson & Johnson Unit DePuy Synthes Acquires Expanding Innovations, A Maker Of Expandable Implant Technology For Spinal Surgery; Financial Terms Not Disclosed"
              },
              {
                "id": 140918128,
                "url": "https://finnhub.io/api/news?id=f1402859602ca724ecf65893e4e4f5820ae506617dde2d10a6da383be625d1ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.",
                "category": "company",
                "datetime": 1784185971,
                "headline": "SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot"
              },
              {
                "id": 140916511,
                "url": "https://finnhub.io/api/news?id=e300002b4f43068403e89c192b53b22aa9c3919d052a002385f9017f92ad7e63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors didn't seem to think so after the company published it.",
                "category": "company",
                "datetime": 1784173167,
                "headline": "Is Johnson & Johnson a Buy After Its Latest Earnings Report?"
              },
              {
                "id": 140925261,
                "url": "https://finnhub.io/api/news?id=9f5bb9cd16e73156160575776209683ad183e46e25dbce73d4396b83af3a0168",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.\nThis transcript is brought to you by Benzinga APIs. For real-time access to",
                "category": "company",
                "datetime": 1784166947,
                "headline": "Full Transcript: Johnson & Johnson Q2 2026 Earnings Call"
              },
              {
                "id": 140915424,
                "url": "https://finnhub.io/api/news?id=ab8372ecfee687d7abf018b7dce66c686ad6cd08febf8c3946af69c275a4cd45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "How do you find the best dividend stocks to buy? Income investors know there's no substitute for regular dividend increases over the long haul.",
                "category": "company",
                "datetime": 1784150433,
                "headline": "Best Dividend Stocks to Buy for Dependable Dividend Growth"
              },
              {
                "id": 140914231,
                "url": "https://finnhub.io/api/news?id=f0632b36b806d3d0cb47d42432e310a59cbd17a7770bb0e0c19a70aac93b683c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wholesale inflation data cooled while major earnings season kicked off positively, lifting stocks across the board, today, July 15, 2026.",
                "category": "company",
                "datetime": 1784150173,
                "headline": "Stock Market Today, July 15: Markets Rise on Cooler Inflation and Strong Earnings Start"
              },
              {
                "id": 140914232,
                "url": "https://finnhub.io/api/news?id=895aec057b4e3597ccabce3d9f9e117a9483c72895b973727e2a43ca3def1bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.",
                "category": "company",
                "datetime": 1784149262,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ..."
              },
              {
                "id": 140912812,
                "url": "https://finnhub.io/api/news?id=d1dbf1f7ea79f9594822717b2881011dd0b4feefcaa01d1669fa51610f4a8da0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...",
                "category": "company",
                "datetime": 1784144040,
                "headline": "Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies"
              },
              {
                "id": 140912813,
                "url": "https://finnhub.io/api/news?id=af3b9436f23bb6328aa43e6b3e1faf8d7dd198364bfa6e28cf7cd911df9289f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.",
                "category": "company",
                "datetime": 1784140381,
                "headline": "The Open Questions On ISRG Stock"
              },
              {
                "id": 140911280,
                "url": "https://finnhub.io/api/news?id=20b0d88f50adb6770ced929f134ea877401a5f178c1c8488b3933a62a362de03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State",
                "category": "company",
                "datetime": 1784137282,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 140911186,
                "url": "https://finnhub.io/api/news?id=d2612052d9f84c92d994a744608379e467802d35adcdb495958f835110241182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.",
                "category": "company",
                "datetime": 1784136544,
                "headline": "Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price"
              },
              {
                "id": 140911295,
                "url": "https://finnhub.io/api/news?id=4a791776ab37db358676e8be6b305d1ec3123f5214f8c1346ecc26403cfddb47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PayPal stock leads the S&P 500 while Sandisk is among the worst performers. Micron falls as chip stocks book significant losses.",
                "category": "company",
                "datetime": 1784134800,
                "headline": "Micron, PayPal, IBM, SpaceX, BlackRock, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140911296,
                "url": "https://finnhub.io/api/news?id=aee602b293e01bdae62f2d6674938ab67845e74bf45b3536a1bd3aa55fdad064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.",
                "category": "company",
                "datetime": 1784134793,
                "headline": "J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others"
              },
              {
                "id": 140910530,
                "url": "https://finnhub.io/api/news?id=d3f52428a05de534ed0291c48948492f6aadc30b433f1701d5322f7b8d1fb595",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784133603,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140911297,
                "url": "https://finnhub.io/api/news?id=787e4c2e5b8b34dbaa7ba190f36e70608d9c07c20239be6b5eb232e1e3172fd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.",
                "category": "company",
                "datetime": 1784132843,
                "headline": "Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King"
              },
              {
                "id": 140912735,
                "url": "https://finnhub.io/api/news?id=8a8b81142b9c7e4bb5438d07823228179787f4ff25c9657eff00ab62eca89eb8",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk -...",
                "category": "company",
                "datetime": 1784131079,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140909590,
                "url": "https://finnhub.io/api/news?id=88fcc255731ec69886d1295814f3e784ca3de4fa2badc7f414c8666b92de4cbb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three major US stock indexes were up in late-morning trading Wednesday, as technology stocks led",
                "category": "company",
                "datetime": 1784130649,
                "headline": "Top Midday Stories: PayPal Reportedly Gets Acquisition Offer From Stripe, Advent; ASML Misses Q2 EPS, Sales Estimates, Lifts Outlook"
              },
              {
                "id": 140909591,
                "url": "https://finnhub.io/api/news?id=7f9bf71fadecdd9a92d2d7c8741a7205f9c570edb10edb3efdbbed51786a82c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s  second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed.  J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”",
                "category": "company",
                "datetime": 1784128500,
                "headline": "Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory"
              },
              {
                "id": 140909592,
                "url": "https://finnhub.io/api/news?id=007d15c9cf8e2ff35d41bbed5ecbb0afd386fd8bd943e6f92ab6307e2cfd496b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.",
                "category": "company",
                "datetime": 1784128454,
                "headline": "J&J raises FY26 outlook following positive Q2"
              },
              {
                "id": 140909593,
                "url": "https://finnhub.io/api/news?id=d077f71ff7fbd751fd25832e105b62d8886c21a60d7ea11acb36a69a781e58a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...",
                "category": "company",
                "datetime": 1784128337,
                "headline": "Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time"
              },
              {
                "id": 140911298,
                "url": "https://finnhub.io/api/news?id=68daeb1521e8e1d59a5f8a5092dccf50dc34cd5e70838a036646bc5876a08361",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Producer Inflation Cools in June",
                "category": "company",
                "datetime": 1784127300,
                "headline": "Producer Inflation Cools in June"
              },
              {
                "id": 140909594,
                "url": "https://finnhub.io/api/news?id=ec340f83e790a33d8578eaabbe70e16e33fdc6e6b4e59590d771d0a8d3a886df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.",
                "category": "company",
                "datetime": 1784127000,
                "headline": "J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised"
              },
              {
                "id": 140909595,
                "url": "https://finnhub.io/api/news?id=734ecd32e0b0bb076cabb9c846905c77fbf49fb3332c67befbe8f37a58387e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?",
                "category": "company",
                "datetime": 1784126640,
                "headline": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?"
              },
              {
                "id": 140909596,
                "url": "https://finnhub.io/api/news?id=ccd29988ec70f94492a68a9bfcc87fe887cf810dd56988d4d935a873da283740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...",
                "category": "company",
                "datetime": 1784126520,
                "headline": "Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance"
              },
              {
                "id": 140909597,
                "url": "https://finnhub.io/api/news?id=d56e980eea938f5552ae174918377651845cf671b35640abd87fa2e22973148a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.",
                "category": "company",
                "datetime": 1784125920,
                "headline": "PPI Slides in June on Lower Oil Prices, Q2 Results Continue"
              },
              {
                "id": 140909598,
                "url": "https://finnhub.io/api/news?id=7dab795452149bd3414880bc74c107b79159251545e9f97ed6871bfed9ab6e77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "FEATURE  Stocks were rising Wednesday, building on recent gains, as a cooler-than-expected producer price index print boosted investor sentiment. Wall Street also assessed another batch of quarterly earnings reports with chip-machine supplier ASML  offering an encouraging read on the artificial-intelligence trade.",
                "category": "company",
                "datetime": 1784125260,
                "headline": "Intel, Marvell, PayPal, IBM, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140909599,
                "url": "https://finnhub.io/api/news?id=02bc3408b143d0b0d2c85943c9e5093fa90ca7d4d087bd71c3ae77d3510fbd3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.",
                "category": "company",
                "datetime": 1784124278,
                "headline": "Johnson & Johnson Q2 Earnings Call Highlights"
              },
              {
                "id": 140909600,
                "url": "https://finnhub.io/api/news?id=1d6738c6d9a78ffd93f1b782aa95276bb3cb97c56d5097551f9eecc53a118792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Walmart and Johnson & Johnson both beat estimates this quarter, but the way each giant is spending its capital tells two completely different stories about where defensive investing actually pays off right now.",
                "category": "company",
                "datetime": 1784124027,
                "headline": "Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner"
              },
              {
                "id": 140908252,
                "url": "https://finnhub.io/api/news?id=e4f75f3b4d5bc9653feb149741bd86881e2f09000474bc9c816c18cdfe4b02f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expect",
                "category": "company",
                "datetime": 1784123441,
                "headline": "Johnson & Johnson Lifts Full-Year Outlook Following Second-Quarter Beat"
              },
              {
                "id": 140908253,
                "url": "https://finnhub.io/api/news?id=f8e971a5a6caad75bc55b5177e35e9617e2d8fa27564a81e9ef8f0b6a46646a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]",
                "category": "company",
                "datetime": 1784123188,
                "headline": "Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment"
              },
              {
                "id": 140909601,
                "url": "https://finnhub.io/api/news?id=b5061df4902a47af987466427333da6c9fe92bdb416e459fa06f1c832924ea69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1784122204,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 140908133,
                "url": "https://finnhub.io/api/news?id=480ecd1efdac3a227829eb7883cc5a86f40c88e0b34b3e5bcfe8c909920a0c06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1784120409,
                "headline": "Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"
              },
              {
                "id": 140908255,
                "url": "https://finnhub.io/api/news?id=cc258d3da9ae53838311586792668a5eb94f9b6a67e133c42920618179502504",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.",
                "category": "company",
                "datetime": 1784119721,
                "headline": "Healthcare Bellwether J&J Beats And Raises, But Shares Dip"
              },
              {
                "id": 140910451,
                "url": "https://finnhub.io/api/news?id=8adf3a174d992a7822510053eb8715506de936528378933346c11d59ad88c317",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1159967002/image_1159967002.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Tech analyst Dan Ives, known for his bullish calls on stocks like Apple (AAPL) and AI names announced that he has teamed up with Yorkville Securities to form a new kind of merchant bank.",
                "category": "company",
                "datetime": 1784118720,
                "headline": "Wall Street Lunch: Dan Ives Teams Up With Yorkville Securities To Launch Merchant Bank"
              },
              {
                "id": 140908256,
                "url": "https://finnhub.io/api/news?id=96eb4c84d427590062d9d4cf07c341c0c76f5da3bf6ed65246a738b27ba4dff8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "News of the day for July 15, 2026",
                "category": "company",
                "datetime": 1784117187,
                "headline": "5 Things to Know Before the Stock Market Opens on Wednesday"
              },
              {
                "id": 140908257,
                "url": "https://finnhub.io/api/news?id=dffcbd487144d4902ca503dee639eaaf4fee28eafeab18706d3f53e33252bd4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US equity futures were edging higher pre-bell Wednesday as traders considered the latest inflation d",
                "category": "company",
                "datetime": 1784117178,
                "headline": "US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"
              },
              {
                "id": 140908248,
                "url": "https://finnhub.io/api/news?id=edd8af44fdbc11a7818dc1e61ec4669942ac8cd0ad4a1001892de1ac2f9b1a85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.",
                "category": "company",
                "datetime": 1784117108,
                "headline": "Dow Jones Futures: Techs Rise, Oil Hits $80 On Iran News, ASML, Morgan Stanley Lead Earnings Movers"
              },
              {
                "id": 140908259,
                "url": "https://finnhub.io/api/news?id=4bd6543c66cee9ca607ffacfe474a01c59fd8ff61427054401f77309c9bfbbee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Picture two retirees with identical $1.5 million portfolios throwing off $80,000 a year in taxable portfolio income. One lives in Naples, Florida. The other lives in San Diego. If that income is taxed as ordinary income and falls in California’s 9.3% bracket, the California retiree could lose about $7,440 a year to state income tax ... The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year",
                "category": "company",
                "datetime": 1784116945,
                "headline": "The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year"
              },
              {
                "id": 140908260,
                "url": "https://finnhub.io/api/news?id=25d2f4579b69c5e41cd7ab96a5efc1ac5cbc9866e68f0703118c2c0ea471ad90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint",
                "category": "company",
                "datetime": 1784116917,
                "headline": "Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength"
              },
              {
                "id": 140907340,
                "url": "https://finnhub.io/api/news?id=a4991ce4f683f91b710365cca22adbf8237f8b0e8a06f4416b51ca7ee2a6bae8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.",
                "category": "company",
                "datetime": 1784115687,
                "headline": "Dow Jones Futures: Oil Prices Hit $80 On Iran News, ASML, Morgan Stanley Lead Earnings Movers"
              },
              {
                "id": 140908261,
                "url": "https://finnhub.io/api/news?id=2a1b2e7c2e336f9a72b568b5ac722ab04c6ed98c7f6cdafa9f706f35418c5d37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson  raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara.  The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.",
                "category": "company",
                "datetime": 1784115480,
                "headline": "Why Johnson & Johnson Stock Is Falling Even After a Guidance Hike"
              },
              {
                "id": 140909365,
                "url": "https://finnhub.io/api/news?id=76a3181bef3b2c7150e33ad598c8a16d2c5b4eb03982ca724028760ddb0d572e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266159678/image_2266159678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson Q2 2026 results: 6.6% revenue growth, Pharma/MedTech strength, and dividend stability. Click for this JNJ earnings update.",
                "category": "company",
                "datetime": 1784115253,
                "headline": "Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street"
              },
              {
                "id": 140908262,
                "url": "https://finnhub.io/api/news?id=a3c02aed2f2d9e07701c9501ce2b08e8169b8f19ffb57cb4a98f015f765f168f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784115002,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 140907559,
                "url": "https://finnhub.io/api/news?id=1fcb7f84b47d3bc10563f5ccefe5eebb163514c3e049267d25c046760da9f4a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks look set to build on their recent gains as investors try to make sense of another batch of quarterly earnings reports.",
                "category": "company",
                "datetime": 1784114820,
                "headline": "Intel, Johnson & Johnson, ASML, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140907215,
                "url": "https://finnhub.io/api/news?id=572fb61f26bb74b899035732346e05f98565a6037204b53e0381a10ee1e45214",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "J&J reported Q2 earnings in line with estimates, raised full-year guidance for sales and EPS, yet saw muted market reaction with stock down ~1.9% pre-market.",
                "category": "company",
                "datetime": 1784114488,
                "headline": "Johnson & Johnson (NYSE:JNJ) Raises Full-Year Guidance After In-Line Q2 Results"
              },
              {
                "id": 140907439,
                "url": "https://finnhub.io/api/news?id=76dbabe7c9bad302caf7f990b149c1d0f961308d4c92e74ca73b24759b95cb82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.",
                "category": "company",
                "datetime": 1784114094,
                "headline": "Johnson & Johnson tops second-quarter forecasts and lifts guidance despite premarket decline (JNJ)"
              },
              {
                "id": 140907440,
                "url": "https://finnhub.io/api/news?id=d4fc0e49f6e84d53b084291f70ad0fbf1c7a69ea8a5e79f1be0d2c5663bcdcba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.",
                "category": "company",
                "datetime": 1784113435,
                "headline": "Johnson & Johnson beats estimates but shares dip"
              },
              {
                "id": 140907441,
                "url": "https://finnhub.io/api/news?id=ba0258ea77d7da09c8ab76bbdbc2029b8a4ec44098d830ba03fc4e837e4aab91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson will release its second-quarter earnings report before the opening bell on Wednesday, July 15. Analysts expect the company to report quarterly earnings of $2.85 per share, up from $2.77 per share in the year-ago period. The consensus...",
                "category": "company",
                "datetime": 1784112366,
                "headline": "How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings"
              },
              {
                "id": 140907442,
                "url": "https://finnhub.io/api/news?id=d1efded5187965b2a59a2176420140c6e70982a359b4b270f05f5ecdfea4f944",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 15, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026.",
                "category": "company",
                "datetime": 1784111100,
                "headline": "Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026"
              },
              {
                "id": 140907443,
                "url": "https://finnhub.io/api/news?id=c49fb7ab1c6a5837fa280079290342e09b697867de272310a858fd2028764223",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor",
                "category": "company",
                "datetime": 1784110920,
                "headline": "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026"
              },
              {
                "id": 140907444,
                "url": "https://finnhub.io/api/news?id=4f08eae507e1193ecb087dcc13a87d4db5cffa3d7fa6b20ed072017e691b054f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 15, 2026--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. \"Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,\" said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. \"With raised guidance and quarterly sales surpassin",
                "category": "company",
                "datetime": 1784110800,
                "headline": "Johnson & Johnson reports Q2 2026 results, raises 2026 outlook"
              },
              {
                "id": 140907445,
                "url": "https://finnhub.io/api/news?id=845f41dc98196ae4fdb92ce50ceddd355048dd46df86616dbd3b41d7db42e9cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eight thousand dollars a month is the kind of retirement income target that looks simple until the yield math starts moving underneath it. It translates to $96,000 a year, but the portfolio needed to produce that income can vary by well over $1 million depending on whether the investor accepts a 3.5% yield, a 6% ... What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield",
                "category": "company",
                "datetime": 1784110629,
                "headline": "What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield"
              },
              {
                "id": 140907446,
                "url": "https://finnhub.io/api/news?id=2d02d5cf0d75ca0cae255786ac3585d494c1f5d01af68e5d8c01eab28b11bce2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks looked set to rise again on Wednesday, building on gains from the previous session that were powered by a solid start to the second-quarter earnings season and cooler-than-expected inflation data.  Nasdaq 100 futures added 0.4%.  Dow Jones Industrial Average futures rose 81 points, or 0.2%.",
                "category": "company",
                "datetime": 1784110182,
                "headline": "Stock Futures Jump. Market Rally Gathers Pace as Earnings Season Ramps Up."
              },
              {
                "id": 140911822,
                "url": "https://finnhub.io/api/news?id=fa17715f1b72478afab6a288d6534679bb604cbc46e9c70eb3af7c4aabfe45b6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.",
                "category": "company",
                "datetime": 1784107911,
                "headline": "Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook"
              },
              {
                "id": 140910786,
                "url": "https://finnhub.io/api/news?id=c4a2d146e21fb7daa47e67c402fb3a6be0643ebcff00aa0e2b61cce8bc1a91ef",
                "image": "https://image.cnbcfm.com/api/v1/image/108260658-17701229642026-02-03t122144z_241610661_rc2bejauv8r4_rtrmadp_0_paypal-results.jpeg?v=1770122981&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1784100829,
                "headline": "Stocks making the biggest moves premarket: BlackRock, PayPal, ASML, Morgan Stanley & more"
              },
              {
                "id": 140910787,
                "url": "https://finnhub.io/api/news?id=0a6f3fe8f6935b5badfdfb4b9e31644dc77a38f0ee71f38c650e4c414cc302f2",
                "image": "https://image.cnbcfm.com/api/v1/image/108335230-4ED1-MC-071526-Vamil.jpg?v=1784114956&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Vamil Divan, Senior Biopharma Research Analyst at Guggenheim Securities, said Johnson & Johnson has moved past patent losses and is benefiting from a strong pipeline of new products driving future growth.",
                "category": "company",
                "datetime": 1784100565,
                "headline": "Vamil Divan: We are looking for accelerating growth into 2027"
              },
              {
                "id": 140908853,
                "url": "https://finnhub.io/api/news?id=89e4833a9fa20ccd77cb554da88c61423a07541323a70d40a9fcab10af32f087",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Companies Reporting Before The Bell\n• VCI Global (NASDAQ:VCIG) is estimated to report earnings for its Fiscal Year 2025. \n• PNC Financial Services Gr (NYSE:PNC) is projected to report quarterly earnings at $4.43 per",
                "category": "company",
                "datetime": 1784099470,
                "headline": "Earnings Scheduled For July 15, 2026"
              },
              {
                "id": 140911824,
                "url": "https://finnhub.io/api/news?id=11a8881829fa4914e6ee2fc5098e938c170e5ed482291fd038de8dbfa2c660f6",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": " Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the",
                "category": "company",
                "datetime": 1784096758,
                "headline": "Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoY"
              },
              {
                "id": 140911825,
                "url": "https://finnhub.io/api/news?id=03d694a3a8b38f252ce1e205d13eeb0463233f273a356f676bb5de03344a8c5b",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 analyst estimate. Raises FY2026 sales outlook from $100.300 billion-$101.300 billion to $100.800",
                "category": "company",
                "datetime": 1784096536,
                "headline": "Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est"
              },
              {
                "id": 140911826,
                "url": "https://finnhub.io/api/news?id=7ba5559f31c8d34a08ffe13e149cac885181af43fa70368300ee8346b21d1074",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "]",
                "category": "company",
                "datetime": 1784096449,
                "headline": "Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate"
              },
              {
                "id": 140908855,
                "url": "https://finnhub.io/api/news?id=0bd9ec8d7935ec4e27c1dc576e933c71816c604d8f0f286f1acb887ea775203b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/People-Silhouettes-On-American-Stock-Mar.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "July 15, 2026: Polymarket traders expect the S&P 500 to open higher on Wednesday after cooler inflation sharply reduced July Fed hike expectations.",
                "category": "company",
                "datetime": 1784089520,
                "headline": "Stock Market: Will S&P 500 Open Up or Down Today?"
              },
              {
                "id": 140910605,
                "url": "https://finnhub.io/api/news?id=cc8b2768dae29ccd6206162d2aecd5c2e53559f0e95747d25b043050577d0301",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "CNN Money Fear and Greed index improved, but remained in Fear zone. U.S. stocks mostly higher on inflation data.",
                "category": "company",
                "datetime": 1784085469,
                "headline": "Nasdaq Gains Over 200 Points Following Inflation Report: Investor Sentiment Improves, Greed Index Remains In ‘Fear' Zone"
              },
              {
                "id": 140910606,
                "url": "https://finnhub.io/api/news?id=7931fb5218a4714b2f3aead3ebddba4767322b6b545a5af35cbc89c7d60d1f5a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/London--United-Kingdom---February-26--20.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley, Pentair, Johnson & Johnson expected to release earnings, ASML posts strong results, Progressive to report",
                "category": "company",
                "datetime": 1784082564,
                "headline": "Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday"
              },
              {
                "id": 140904169,
                "url": "https://finnhub.io/api/news?id=767d2ade90ef611607c1a4bca821949c13486a341ca98a855029fee95d289c7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.",
                "category": "company",
                "datetime": 1784072870,
                "headline": "Dow Jones Futures Rise; Goldman, CrowdStrike Jump, But AI Stocks Need To Do This"
              },
              {
                "id": 140902827,
                "url": "https://finnhub.io/api/news?id=1f6b453f31d34dccef7a765a871c263304660a1877335a34668902c89bd77538",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.",
                "category": "company",
                "datetime": 1784062760,
                "headline": "Dow Jones Futures: Goldman, CrowdStrike Jump, AI Stocks Need To Do This; ASML, Morgan Stanley Due"
              },
              {
                "id": 140910779,
                "url": "https://finnhub.io/api/news?id=e36c920525aaa0874fb55e565da7f7840590e65eeb85912374ef661a4127c708",
                "image": "https://image.cnbcfm.com/api/v1/image/108324283-17818184352026-06-18t212644z_311932191_rc2kwlaz3beo_rtrmadp_0_usa-stocks.jpeg?v=1781818551&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Stocks closed higher on Tuesday, helped by signs of easing inflation, which boosted investor hopes that the Federal Reserve can hold off on rate hikes for the moment.",
                "category": "company",
                "datetime": 1784056328,
                "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140901110,
                "url": "https://finnhub.io/api/news?id=a418695849289d29baabb02fccad0cc1323fa81f759a05f46d8ec554e1e50864",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1784056204,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 140901466,
                "url": "https://finnhub.io/api/news?id=3b28393a5831026f9ac3732237381ea888082eee864a93bb498cf961a423a22f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.",
                "category": "company",
                "datetime": 1784052407,
                "headline": "The Paid-To-Hold Play On ISRG Stock: A 12% Income"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140902248,
                "url": "https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.",
                "category": "company",
                "datetime": 1784047680,
                "headline": "A Fresh Look At Syndax Pharmaceuticals"
              },
              {
                "id": 140899749,
                "url": "https://finnhub.io/api/news?id=84094e3225d70c38db6c6d50a9e1c231ea6494cc942138536531dc77bf34a499",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.",
                "category": "company",
                "datetime": 1784046620,
                "headline": "This Healthcare Giant Still Checks Every Box for Long-Term Investors"
              },
              {
                "id": 140902323,
                "url": "https://finnhub.io/api/news?id=328fd13fc461312f4abaa2aa4d14fd146e994b9dd8b50474f58fe81e55a60d67",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/Marketplace-Enrollment-Declines.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Earnings for ASML, Progressive, and BNY Mellon are coming with implied moves of 3.89%, 3.89%, and 4.14% respectively, reflecting market expectations for post-print repricing risk.",
                "category": "company",
                "datetime": 1784046094,
                "headline": "ASML Could Swing 7.5% After Earnings on Wednesday"
              },
              {
                "id": 140899750,
                "url": "https://finnhub.io/api/news?id=804eb2632a3ad3085591338bd6e8d9f028e77cc907f15421b301c5d84b07d50e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $1.4 million nest egg is far above the typical U.S. retirement account balance, but the check it writes each month depends entirely on how the assets are arranged. At a 3.5% yield, the portfolio produces $49,000 a year. At a 10% yield, it produces $140,000. The difference looks simple on a spreadsheet, but it ... A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets",
                "category": "company",
                "datetime": 1784045547,
                "headline": "A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140898076,
                "url": "https://finnhub.io/api/news?id=f40aa289b2dde6583d36a61262e45aaeea6e34024e49b68b4911c34191600fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.",
                "category": "company",
                "datetime": 1784039400,
                "headline": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results"
              },
              {
                "id": 140898077,
                "url": "https://finnhub.io/api/news?id=bfd8f460c4d367b16145d1b4ffd79af32bdd28c9d051cfdbb4030e02693a8e59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock has returned 77.8% over the past five years and now sits at a point where a Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside while the broader valuation checks look much less generous. A 77.8% five year return sets the context for assessing whether today’s price still leaves enough potential reward for the risk involved. Progress in oncology and autoimmune drugs can support long term cash flow expectations, while ongoing talc related...",
                "category": "company",
                "datetime": 1784038477,
                "headline": "Johnson & Johnson (JNJ) Stock May Be Reasonable After Talc Verdict Ruling"
              },
              {
                "id": 140898078,
                "url": "https://finnhub.io/api/news?id=662432f9abe149819b5e3060f6fa533bf33f671aa0c5610830a23d64bd69986f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "San Francisco makes passive income math unforgiving. SmartAsset’s 2026 comfort-salary study estimates that a single adult needs about $134,950 in pretax income to live comfortably in the city, among the highest figures in the country. Turning that paycheck into dividend income is not just a yield exercise. The yield an investor reaches for changes both ... A Dividend Portfolio That Can Cover the Cost of Living in San Francisco",
                "category": "company",
                "datetime": 1784037813,
                "headline": "A Dividend Portfolio That Can Cover the Cost of Living in San Francisco"
              },
              {
                "id": 140898041,
                "url": "https://finnhub.io/api/news?id=f81b5704db160b35b4aa4e9fe38b791120b54b59fe0684be4ae1b6f05f59f94e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.",
                "category": "company",
                "datetime": 1784037240,
                "headline": "Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge"
              },
              {
                "id": 140896860,
                "url": "https://finnhub.io/api/news?id=69cac81872a917b82ac0a4526f38f4b08928a2ae81ab419989126f3ac804ca95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.",
                "category": "company",
                "datetime": 1784033543,
                "headline": "ISRG Stock: What Does Its Valuation Imply?"
              },
              {
                "id": 140896861,
                "url": "https://finnhub.io/api/news?id=50ca3d5ebf3ad6a5d9c62186736be99edd52483da4c3f0093b6e6925bb8eca50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A series of big bank results kicked off the second quarter earnings season on Tuesday.",
                "category": "company",
                "datetime": 1784030838,
                "headline": "Earnings live: Wall Street bank stocks mixed despite profit haul"
              },
              {
                "id": 140899751,
                "url": "https://finnhub.io/api/news?id=d1aa5a730c62073f57143bd0a22d3a9540c6140220402a1e4e9ae24f822d7381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.",
                "category": "company",
                "datetime": 1784030400,
                "headline": "Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill"
              },
              {
                "id": 140903560,
                "url": "https://finnhub.io/api/news?id=4de721486aee9a85d315832d79e4a7091464b812938b3bfd4f046dad27e0b9b1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock trades near all-time highs. A strong Q2 report and the chart show more upside ahead.",
                "category": "company",
                "datetime": 1784030120,
                "headline": "Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’"
              },
              {
                "id": 140895304,
                "url": "https://finnhub.io/api/news?id=157f7c5da8ff0a5e4f2a825c575e945d68e2085c942ec86685abf546d23b7c5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Opportunities include integrating cardio-renal strategies, aligning therapies with real-world evidence, leveraging site-of-care economics, and enhancing supply resilience amid tariff influences. Late Stage Chronic Kidney Disease Therapeutics Market Late Stage Chronic Kidney Disease Therapeutics Market Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The \"Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering.The Late Stage",
                "category": "company",
                "datetime": 1784016960,
                "headline": "Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape"
              },
              {
                "id": 140895245,
                "url": "https://finnhub.io/api/news?id=083d10d3df50abc007cf7a68b661f56bc381dc0eef52cb3dc0a00a03b28e8bf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The dividend looks secure. The share price is the harder call.",
                "category": "company",
                "datetime": 1784016060,
                "headline": "This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?"
              },
              {
                "id": 140892514,
                "url": "https://finnhub.io/api/news?id=b85633b633036327b86c0744adb5fccb38fa08d2530290494286e8859a41fa44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "After hitting fresh all-time highs last week, investors are turning their attention to JNJ's Q2 report, which is scheduled for Wednesday, July 15, before the opening bell.",
                "category": "company",
                "datetime": 1783979400,
                "headline": "Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?"
              },
              {
                "id": 140891291,
                "url": "https://finnhub.io/api/news?id=70d70f99824f8bcd6503316a221bd6d1b30ecdf59e8dfb17ad8bd115267f3c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with market moves at the end of the day.) Equities on Wall Street fell Monday, snapping",
                "category": "company",
                "datetime": 1783975302,
                "headline": "Update: Nasdaq Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran Tensions"
              },
              {
                "id": 140889992,
                "url": "https://finnhub.io/api/news?id=5c60b34df24e7ae144e94c72b25a9ce7b052938d9182985218906432e122789c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Social Security benefits come with inflation protection, but the tax formula attached to those benefits does not. For retirees with pensions, IRA withdrawals, taxable investment income, or municipal bond interest, a larger benefit can quietly mean a larger federal tax bill. The result is a tax rule from the 1980s that reaches more retirees every ... How Much of Your Social Security Will You Actually Keep After Taxes?",
                "category": "company",
                "datetime": 1783967289,
                "headline": "How Much of Your Social Security Will You Actually Keep After Taxes?"
              },
              {
                "id": 140889066,
                "url": "https://finnhub.io/api/news?id=6c4da60e3f458aee87f8080c7136136deca2a95a5b07afe2220895b88f67aaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US benchmark equity indexes were lower intraday, while oil prices jumped as President Donald Trump s",
                "category": "company",
                "datetime": 1783966889,
                "headline": "Equities Fall Intraday, Oil Soars as Trump Reinstates Iranian Shipping Blockade in Hormuz"
              },
              {
                "id": 140888392,
                "url": "https://finnhub.io/api/news?id=39384362546aba63a4bdfcb9862c1f6ebc3805d8f428319157998c59d8b43bb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the",
                "category": "company",
                "datetime": 1783962000,
                "headline": "Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight"
              },
              {
                "id": 140888393,
                "url": "https://finnhub.io/api/news?id=be7524a6a82f777e2943b1fa2d1bdb5a220852a4ed4bc08e478968a3127e2c97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.",
                "category": "company",
                "datetime": 1783960680,
                "headline": "Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 242,
            "discarded_article_count": 220
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.3,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(15.8%→6.8%)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 8808240,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 8527750,
              "avg_vol_20": 8440550,
              "avg_vol_30": 8808240,
              "range_pct_10": 0.06849874312939368,
              "range_pct_20": 0.09000331177876267,
              "range_pct_30": 0.15763747350041246,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9681559539703732,
              "dist_to_20d_high": 0.012767695236896227,
              "down_shrink_days": 2,
              "breakout_level_20d": 269.42999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.4345333733683219
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.2570774185900753,
              "turnoverUsdM": 2662.7193938939995,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 253.9828,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.5,
            "take_profit_price": 280.8189,
            "target_multiplier": 1.9,
            "technical_strength": 1.95,
            "take_profit_percent": 5.6
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.240542294623226,
          "stopLossPercent": 4.5141548371801505,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.JNJ",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 6.0036,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.26
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 131.06
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0561
    },
    "kdj": {
      "d": 58.59,
      "j": 111.08,
      "k": 76.09,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 38.39
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 53959100,
      "recentSlope": 4392130,
      "previousSlope": -1489690
    },
    "rsi": 48.73,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 245.8544,
      "position": "SAR喺價下",
      "distancePct": 7.57,
      "previousTrend": "上升"
    },
    "ma50": 242.6422,
    "macd": {
      "macd": 4.617425551751381,
      "trend": "強烈看漲",
      "signal": 4.446486318866424,
      "histogram": 0.17093923288495727
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 256.6639,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 4
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.23,
      "score": 6,
      "avgVolume": 8125240,
      "currentVolume": 10010600
    },
    "derived": {
      "ma20": 257.046,
      "ma50": 242.6422,
      "prevClose": 263.4,
      "avgVolume10": 9001590,
      "avgVolume20": 8125240,
      "changePercent": 0.98,
      "avgVolumeForScore": 8125240
    },
    "ma_cross": {
      "ma20": 257.046,
      "ma50": 242.6422,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 256.4795,
      "prevMa50": 241.9308,
      "spreadPct": 5.94,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 245.8706,
      "upper": 268.2214,
      "position": "上半部"
    },
    "rsi_short": 80.27,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.23
    }
  }
}

{
  "close": 265.99,
  "volume": 10010600,
  "changePercent": 0.98
}